Clin Cancer Res: Thyroid hormone replacement therapy makes breast cancer patients have a poor prognostication.

Thyroid disease is a common concomititation of breast cancer (BC) in women, and many patients require thyroid hormone (TH) replacement therapy (THRT).
researchers have conducted an observational study to verify that THRT can produce harmful clinical effects through mechanisms such as hormone interactions, nucleo-subject intersections, and high-risk BC gene uptence.
study looked at BC patients with lymph nodes negative (LN-) (n=820 and n=160) to test the interaction between THRT and clinical, histological, prognostic and therapeutic variables.
the number of patients, treatment time, follow-up time, tumor size, occurrence rate, tumor type and treatment drug plan and dose between the two groups.
the potential mechanisms of the THRT effect using chip and molecular methods in in vitro and in vitro models.
effects of THRT therapy in both long-term observational studies, THRT significantly and independently reduced the total disease-free and BC-specific survival of patients with steroid-positive (SR) positive (compared to SR-negative).
tam therapy with the effects of THRT and his moxifen therapy in patients with SR-LN-BC had the shortest survival time in all treatment groups.
effects of aromatase inhibitor (ICI) therapy in patients with a second cohort, the interaction between THRT and aromatase inhibitors was weak.
In in vitro models, TH processing enhances the expression of estrogen and TH-related genes, enhances the co-location of ER and THR, and activates genes that are clinically used to predict the invasiveness of SR-BC tumors, including IGF-IR, WNT, and TGF beta path.
, the study suggests significant adverse interactions between THRT, estrogen, and carcinogenic signals in patients with SR-LN-BC.
.